We are excited to announce that we will participate in PEGS Boston 2025, the premier Protein & Antibody Engineering Summit, on May 12–16, 2025, at Omni Boston Hotel Seaport, MA. This global event experts across academia, biotech, and pharma will discuss the latest biologics, antibody therapeutics, and cell therapy innovations. Come with us to explore the newest developments in biotech!
What is the PEGS Boston Summits
PEGS Boston 2025 is a leading Protein & Antibody Engineering Summit, bringing together 2400+ participants and more than 350 speakers who are biotech, pharmaceutical, and academia experts to discuss biologics research, antibody therapeutics, and protein engineering advancements. The summit focuses on bispecific antibodies, antibody-drug conjugates (ADCs), immunotherapy, and bioprocess optimization, serving as a crucial platform for collaboration, innovation, and progress in drug discovery and biopharmaceutical development.
Event Overview
Date: May 12-16, 2025
Venue: Omni Boston Hotel at the Seaport, 450 Summer Street, Boston, MA
Event Schedule
The PEGS Boston 2025 Summit at the Omni Boston Hotel at the Seaport begins on May 12, 2025. It will feature expert-led sessions on biologics, antibody engineering, immunotherapy, and more. For the full schedule and session details, please refer to: PEGS 2025.
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to seeing you at the PEGS 2025 Boston Summits in Seaport, MA!
